Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum Theodore GREINER, Neil R. BURCH, Robert EDELBERG AMA, Archives of Neurology & Psychiatry, 1958, 79, (2), 208-210. doi:10.1001/archneurpsyc.1958.02340020088016 Abstract Despite 14 years of investigation, as intensive as accorded any biologically active chemical, a gap remains in the systematic description of human response to lysergic acid diethylamide (LSD-25). The dramatic schizophrenic-like symptoms after doses of 40 μg to 100 μg have drawn the main interest. The threshold for activity is placed at 20 μg by general consensus, while perfunctory administration of smaller doses has left their effect uncertain. Accompanying those pharmacologic demonstrations has been [...]
Lire la suiteLSD Psychotherapy Stanislas GROF Hunter House Ed., 1979 LIST OF CONTENTS 1. History of LSD Therapy The Discovery of LSD and its Psychedelic Effects Early Laboratory and Clinical LSD Research Therapeutic Experimentation With LSD Studies of Chemotherapeutic Properties of LSD LSD-Assisted Psychotherapy The Need for a Comprehensive Theory of LSD Therapy 2. Critical Variables in LSD Therapy Pharmacological Effects of LSD Personality of the Subject Personality of the Therapist or Guide Set and Setting of the Sessions 3. Psycholytic and Psychedelic Therapies with LSD : Towards an Integration of Approaches The Search for an Effective Technique of LSD Psychotherapy Advantages and Drawbacks of the Psycholytic Approach Pros and Cons of Psychedelic Therapy 4. Principles of LSD Psychotherapy The Preparation Period Psychedelic Sessions Integration [...]
Lire la suitePsycholytic and Psychedelic Therapy Research 1931-1995 : A Complete International Bibliography Torsten Passie Laurentius Publishers, Hannover, Germany, 1997 Kleine bibliographische Reihe, vol. 3. (Ed. Raimund Dehmlow), ISSN 0941-6617 ISBN 3-931614-83-2 (cloth), ISBN 3-931614-84-0 (pbk) Preface I. Introduction 9 II. Organization of the Bibliography 21 III. Bibliography 1. General Approach and Basic Research 23 2. Psycholytic Therapy 42 3. Psychedelic Therapy 70 IV. Major Scientific Conferences on the Subject 88 V. Major Bibliographic Sources 89 Author Index 90 Subject Index 95 About the Authors 102
Lire la suiteProhibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration Matthew Oram History of Psychiatry, 2016, 27, (3), 290-306. Doi : 10.1177/0957154X16648822 Abstract Over the 1950s and early 1960s, the use of the hallucinogenic drug lysergic acid diethylamide (LSD) to facilitate psychotherapy was a promising field of psychiatric research in the USA. However, during the 1960s, research began to decline, before coming to a complete halt in the mid-1970s. This has commonly been explained through the increase in prohibitive federal regulations during the 1960s that aimed to curb the growing recreational use of the drug. However, closely examining the Food and Drug [...]
Lire la suiteFlashback : Psychiatric Experimentation With LSD in Historical Perspective Erika Dyck Canadian Journal of Psychiatry, 2005, Vol 50, No 7, 381-388. Doi : 10.1177/070674370505000703 In the popular mind, d-lysergic acid diethylamide (LSD) research in psychiatry has long been associated with the CIA-funded experiments conducted by Ewen Cameron at the Allen Memorial Institute in Montreal, Quebec. Despite this reputation, a host of medical researchers in the post–World War II era explored LSD for its potential therapeutic value. Some of the most widespread trials in the Western world occurred in Saskatchewan, under the direction of psychiatrists Humphry Osmond (in Weyburn) and Abram Hoffer (in Saskatoon). These [...]
Lire la suiteEfficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962 Matthew ORAM Journal of the History of Medicine and Allied Sciences, 2012, Volume 69, Number 2, 221-250. doi:10.1093/jhmas/jrs050 ABSTRACT. The decline in therapeutic research with lysergic acid diethylamide (LSD) in the United States over the course of the 1960s has commonly been attributed to the growing controversy surrounding its recreational use. However, research difficulties played an equal role in LSD psychotherapy’s demise, as they frustrated researchers’ efforts to clearly establish the efficacy of treatment. Once the Kefauver Harris Drug Amendments of 1962 introduced the requirement that proof of efficacy be established through controlled clinical [...]
Lire la suiteLSD before Leary - Sidney Cohen' s Critique of 1950s Psychedelic Drug Research Steven J. Novak Isis, 1997, Vol. 88, No. 1, pp. 87-110. http://links.jstor.org/sici?sici=0021-1753%28199703%2988%3A1%3C87%3ALBLSCC%3E2.0.CO%3B2-W ABSTRACT In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychoto-mimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were [...]
Lire la suitePrice elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis Michael Amlung, Derek D. Reed, Vanessa Morris, Elizabeth R. Aston, Jane Metrik & James MacKillop Addiction, 2018, 114, 112–118 doi:10.1111/add.14437 ABSTRACT Background and Aims : The evolving legal status of cannabis world-wide necessitates evidence-based regulatory policies to minimize risks associated with cannabis misuse. A prominent concern is the impact legalization may have on the illegal cannabis market, including whether illegal cannabis will serve as a substitute for legal cannabis. Empirical data on this issue are virtually non-existent. This study used behavioral economics to investigate substitutability of legal and illegal cannabis in legalized catchment areas [...]
Lire la suiteStates Want Pot to Grow Greener as Legal Cannabis Expands Bloomberg Environment, Posted July 19, 2019, 12:01 PM https://news.bloombergenvironment.com/environment-and-energy/states-want-pot-to-grow-greener-as-legal-cannabis-expands Sustainability considered as part of legalization Regulations address pesticides, air quality As more states legalize recreational and medical marijuana, they’re confronting the reality that cannabis production involves using huge amounts of pesticides, energy, and water, while generating tons of plant and packaging waste. The result is a patchwork of air, water, pesticide, and waste regulations for the industry across dozens of states, even as the substance remains illegal at the federal level. States like Michigan, where the Marijuana Regulatory Agency will begin accepting business licenses in [...]
Lire la suiteThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]
Lire la suite